Hans Schambye, Galecto CEO
August 15, 2023 11:09 AM EDT
R&D

Galec­to ax­es lead can­di­date in lung dis­ease af­ter PhI­Ib miss, stock craters

Paul Schloesser

Associate Editor

Galec­to scrapped de­vel­op­ment of its lead can­di­date af­ter the drug missed the pri­ma­ry end­point in a mid-stage lung dis­ease tri­al and said it is eval­u­at­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times